Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis

Experimental and Therapeutic Medicine
Liqiong HouYiyi Zhang

Abstract

Previous randomized controlled trials (RCTs) have reported conflicting results for the efficacy of sitagliptin and sulfonylurea therapy in patients with type 2 diabetes mellitus showing inadequate glycemic control with metformin monotherapy. To clarify these findings, a meta-analysis was conducted of the outcomes of all published RCTs comparing sitagliptin with sulfonylureas in the treatment of type 2 diabetes mellitus. Standard medical databases were searched to identify relevant English- and Chinese-language RCTs. RCT results were compared regarding the mean change in glycated hemoglobin (HbA1c) level; the proportion achieving <7% HbAlc; and a change in body weight. No significant differences were found between the metformin plus sitagliptin and metformin plus sulfonylurea groups regarding HbAlc or the proportion achieving <7% HbAlc, while the metformin plus sitagliptin group experienced fewer hypoglycemic events (P<0.00001) and a greater reduction in body weight (P<0.00001). Metformin plus sitagliptin therapy may decrease HbAlc values in patients with type 2 diabetes mellitus who are not achieving their glycemic targets with metformin monotherapy in a manner similar to metformin plus sulfonylurea therapy, whilst posing a low...Continue Reading

References

Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Silvio E Inzucchi
Sep 30, 2003·Diabetes Care·Daniel J Drucker
Oct 16, 2004·The Journal of Clinical Endocrinology and Metabolism·Kathrin MaedlerMarc Y Donath
Jan 27, 2005·Drugs·Andrew J Krentz, Clifford J Bailey
Jun 9, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·UNKNOWN IDF Clinical Guidelines Task Force
Sep 1, 2007·BMJ : British Medical Journal·Dean T EurichJeffrey A Johnson
Jan 6, 2009·Diabetes Care·UNKNOWN American Diabetes Association
Feb 24, 2009·Current Medical Research and Opinion·Debora Williams-HermanJohn M Amatruda
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
May 12, 2010·International Journal of Clinical Practice·T SeckUNKNOWN Sitagliptin Study 024 Group
Aug 27, 2014·Current Diabetes Reviews·Sayantan Roy ChoudhurySaibal Das

❮ Previous
Next ❯

Software Mentioned

Stata
Review Manager

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.